BACKGROUND: Excessive complement activation is an integral part of ischemia and reperfusion (IR) injury (IRI) of organs. In kidney transplantation, the pathologic consequence of IRI and complement activation can lead to delayed graft function, which in turn is associated with acute rejection. Previous strategies to reduce complement-induced IRI required systemic administration of agents, which can lead to increased susceptibility to infections/immune diseases. The objective of this study was to determine whether an increase in complement control defenses of rat kidney endothelium reduces IRI. We hypothesized that increased complement control on the endothelial barrier reduces IR-mediated complement activation and reduces kidney dysfunction. MATERIALS AND METHODS: Fischer 344 rats underwent left kidney ischemia for 45 min and treatment with a novel fusogenic lipid vesicle (FLVs) delivery system to decorate endothelial cells with vaccinia virus complement control protein (VCP), followed by reperfusion for 24 h. Assessment included renal function by serum creatinine and urea, myeloperoxidase assay for neutrophil infiltration, histopathology, and quantification of C3 production in kidneys. RESULTS: Animals in which the kidney endothelium was bolstered by FLVs+VCP treatment had better renal function with a significant reduction in serum creatinine compared with vehicle controls (P < 0.05). Also, C3 production was significantly reduced (P < 0.05) in treated animals compared with vehicle controls. CONCLUSION: Increasing complement control at the endothelial barrier with FLVs+VCP modulates complement activation/production during the first 24 h, reducing renal dysfunction following IRI.
BACKGROUND: Excessive complement activation is an integral part of ischemia and reperfusion (IR) injury (IRI) of organs. In kidney transplantation, the pathologic consequence of IRI and complement activation can lead to delayed graft function, which in turn is associated with acute rejection. Previous strategies to reduce complement-induced IRI required systemic administration of agents, which can lead to increased susceptibility to infections/immune diseases. The objective of this study was to determine whether an increase in complement control defenses of rat kidney endothelium reduces IRI. We hypothesized that increased complement control on the endothelial barrier reduces IR-mediated complement activation and reduces kidney dysfunction. MATERIALS AND METHODS: Fischer 344 rats underwent left kidney ischemia for 45 min and treatment with a novel fusogenic lipid vesicle (FLVs) delivery system to decorate endothelial cells with vaccinia virus complement control protein (VCP), followed by reperfusion for 24 h. Assessment included renal function by serum creatinine and urea, myeloperoxidase assay for neutrophil infiltration, histopathology, and quantification of C3 production in kidneys. RESULTS: Animals in which the kidney endothelium was bolstered by FLVs+VCP treatment had better renal function with a significant reduction in serum creatinine compared with vehicle controls (P < 0.05). Also, C3 production was significantly reduced (P < 0.05) in treated animals compared with vehicle controls. CONCLUSION: Increasing complement control at the endothelial barrier with FLVs+VCP modulates complement activation/production during the first 24 h, reducing renal dysfunction following IRI.
Authors: K H Murthy; S A Smith; V K Ganesh; K W Judge; N Mullin; P N Barlow; C M Ogata; G J Kotwal Journal: Cell Date: 2001-01-26 Impact factor: 41.582
Authors: Andrew F Ducruet; Brad E Zacharia; Zachary L Hickman; Bartosz T Grobelny; Mason L Yeh; Sergey A Sosunov; E Sander Connolly Journal: Exp Neurol Date: 2009-07-24 Impact factor: 5.330
Authors: Giuseppe Castellano; Rita Melchiorre; Antonia Loverre; Pasquale Ditonno; Vincenzo Montinaro; Michele Rossini; Chiara Divella; Michele Battaglia; Giuseppe Lucarelli; Gennaro Annunziata; Silvano Palazzo; Francesco Paolo Selvaggi; Francesco Staffieri; Antonio Crovace; Mohamed R Daha; Maurice Mannesse; Sandra van Wetering; Francesco Paolo Schena; Giuseppe Grandaliano Journal: Am J Pathol Date: 2010-02-11 Impact factor: 4.307
Authors: Klaus Distelmaier; Christopher Adlbrecht; Johannes Jakowitsch; Susanne Winkler; Daniela Dunkler; Christopher Gerner; Oswald Wagner; Irene M Lang; Markus Kubicek Journal: Thromb Haemost Date: 2009-09 Impact factor: 5.249
Authors: Vannakambadi K Ganesh; Scott A Smith; Girish J Kotwal; Krishna H M Murthy Journal: Proc Natl Acad Sci U S A Date: 2004-06-03 Impact factor: 11.205
Authors: Tathyana F Fensterer; W Brent Keeling; Phani K Patibandla; Sathnur Pushpakumar; Gustavo Perez-Abadia; Philip Bauer; Chirag V Soni; Gary L Anderson; Claudio Maldonado Journal: J Surg Res Date: 2012-10-30 Impact factor: 2.192
Authors: Saif Ahmad; Chirayu Pandya; Adam Kindelin; Kanchan Bhatia; Rafay Chaudhary; Alok Kumar Dwivedi; Jennifer M Eschbacher; Qiang Liu; Michael F Waters; Md Nasrul Hoda; Andrew F Ducruet Journal: Br J Pharmacol Date: 2020-03-04 Impact factor: 8.739